The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What has the presentation of the ELEVATE TN trial taught us?

Dec 16, 2019

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub were pleased to speak to Susan O'Brien, The Chao Family Comprehensive Cancer Center, University of California, Irvine, US. We asked: What has the presentation of the ELEVATE TN trial taught us?

Susan O'Brien discusses the results from the phase III, multicenter, ELEVATE TN study, in elderly patients with previously-untreated chronic lymphocytic leukemia (CLL). She describes the patient outcomes of the three treatment arms. She concludes by explaining the recent approval of acalabrutinib in Australia, US and Canada has given patients more effective, non-chemotherapy, frontline treatment option for CLL.

What has the presentation of the ELEVATE TN trial taught us?